Lantheus (LNTH)
(Delayed Data from NSDQ)
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Lantheus Holdings (LNTH) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 12.00% and 2.11%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lantheus Holdings (LNTH) Q2 Earnings Match Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 0.00% and -3.49%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lantheus Holdings (LNTH) Q1 Earnings Top Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 12.00% and -0.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
LNTH vs. CLPBY: Which Stock Is the Better Value Option?
by Zacks Equity Research
LNTH vs. CLPBY: Which Stock Is the Better Value Option?
LNTH vs. CLPBY: Which Stock Is the Better Value Option?
by Zacks Equity Research
LNTH vs. CLPBY: Which Stock Is the Better Value Option?
Top Ranked Momentum Stocks to Buy for March 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 21st
LNTH vs. CLPBY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LNTH vs. CLPBY: Which Stock Is the Better Value Option?
New Strong Buy Stocks for February 22nd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Lantheus Holdings (LNTH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lantheus Holdings (LNTH) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 26.32% and 6.53%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings (LNTH) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiovascular Systems Posts 2-Year LIBERTY 360 Study Data
by Zacks Equity Research
The 24-month outcome of LIBERTY 360 study by Cardiovascular Systems (CSII) demonstrates a constant relief from major amputation across all Rutherford Classifications (RC).
Lantheus Holdings (LNTH) Tops Q2 Earnings Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 23.81% and -3.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for March 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Should Value Investors Consider Lantheus Holdings (LNTH) Stock?
by Zacks Equity Research
Lantheus Holdings is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
Halyard Health (HYH) Announces Positive Data on COOLIEF
by Zacks Equity Research
Halyard Health's (HYH) positive clinical data on COOLIEF will boost fortunes in the chronic pain space.
TransEntrix Progresses Toward FDA Approval for Senhance
by Zacks Equity Research
TransEnterix's (TRXC) gradual progress toward FDA's approval for Senhance Surgical Robotic System will boost its presence in the lucrative U.S. market.
Surmodics Receives FDA's Approval for PTA Balloon Catheter
by Zacks Equity Research
Surmodics (SRDX) receives FDA's approval for PTA Balloon Catheter, which will boost its presence in the global peripheral artery disease market.
Bruker (BRKR) Strong on Product Launches Amid Currency Woes
by Zacks Equity Research
Bruker (BRKR) continues to see solid contributions from NMR and Nano businesses. Also, a raised guidance is indicative of brighter prospects.
Myriad Genetics Presents Favorable riskScore Test Data
by Zacks Equity Research
Myriad (MYGN) presenting positive riskScore data at the NSGC conference in Columbus, OH buoys optimism. Notably, with riskScore the company intends to boost its myRisk Hereditary Cancer test suite.
McKesson to Gain From Distribution Business Amid Pricing Woes
by Zacks Equity Research
McKesson Corporation's (MCK) Distribution business driven by market growth and acquisitions is expected to aid growth. However, pricing remains a concern.
Phibro Animal Health Expands Globally Amid Tough Competition
by Zacks Equity Research
Phibro (PAHC) is consistently trying to expand globally to counter the tough competition in the animal health and mineral nutrition space.
Thermo Fisher Fundamentals Impressive Amid Tough Competition
by Zacks Equity Research
Thermo Fisher (TMO) continues to gain considerable synergies from FEI acquisition. A raised guidance buoys optimism.